Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat
Tweet Send to a Friend
Jefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
